News
ETON
64.35
+13.97%
7.89
Weekly Report: what happened at ETON last week (1102-1106)?
Weekly Report · 1d ago
Eton Pharmaceuticals Earnings Call Highlights Record Growth
TipRanks · 3d ago
Eton Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Dow Jones · 3d ago
Eton Pharmaceuticals Price Target Raised to $80.00/Share From $68.00 by Canaccord Genuity
Dow Jones · 3d ago
Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80
Benzinga · 3d ago
Eton Pharmaceuticals Stock Gains as 3Q Revenue More Than Doubles
Dow Jones · 3d ago
Eton Pharma jumps after Q3 beat and guidance hike
Seeking Alpha · 3d ago
Eton Pharmaceuticals Price Target Raised to $80.00/Share From $70.00 by HC Wainwright & Co.
Dow Jones · 3d ago
Eton Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80
Benzinga · 3d ago
Eton Pharmaceuticals price target raised to $80 from $70 at H.C. Wainwright
TipRanks · 3d ago
Eton Pharmaceuticals price target raised to $80 from $68 at Canaccord
TipRanks · 3d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 3d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 3d ago
Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 4d ago
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results
NASDAQ · 4d ago
Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion
NASDAQ · 4d ago
Closing Bell Movers: Airbnb up over 10% on earnings beat
TipRanks · 4d ago
Eton Pharmaceuticals Q3 2026 Earnings Call Transcript
Benzinga · 4d ago
Eton Pharmaceuticals Reports Preliminary ET-700 Study Results
TipRanks · 4d ago
More
Webull provides a variety of real-time ETON stock news. You can receive the latest news about Eton Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About ETON
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has over 11 commercial rare disease products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, IMPAVIDO, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjectors. INCRELEX (mecasermin) is used to treat children who are very short for their age because their bodies do not make enough insulin-like growth factor-1 (IGF-1). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. NITISINONE is a prescription medicine used to treat adults and children with a hereditary disease called tyrosinemia type 1 (HT-1). The Company also has licensed United States rights to a rare disease product candidate ASN-001 (timolol topical gel).